Atherosclerosis  >>  niacin extended-release formulation  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
niacin extended-release formulation / Generic mfg.
MCAT, NCT00804843: Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)

Completed
2
100
US
Atorvastatin/niacin extended-release, Lipitor, Niaspan, Atorvastatin, Lipitor, Simvastatin, Zocor
Merck Sharp & Dohme LLC
Carotid Atherosclerosis
10/10
10/10
ALPINE-SVG, NCT01221402: Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis

Completed
2
38
US
extended-release niacin (Niaspan)
North Texas Veterans Healthcare System, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis, Intermediate Saphenous Vein Graft Lesions
10/14
11/15
2008-008006-46: A Randomized Clinical Trial to Evaluate the Effects of High DoseStatin and Niacin Therapy on Excised Plaque Biomarkers in PatientsUndergoing Carotid Endarterectomy (CEA)

 
2
20
Europe
LIPITOR, Niaspan 500 mg Retardtabletten, LIPITOR, Niaspan 500 mg Retardtabletten
Merck & Co., Inc., MERCK & CO., INC.
carotid atherosclerosis
 
10/10

Download Options